The story of copyright's flagship drug presents a nuanced case for investors in the pharmaceutical sector. While initially a tremendous success, producing billions, the exclusivity lapse and the subsequent flood of off-brand competitors have considerably changed earnings. This raises questions about the ongoing sustainability of similar medication